Levetiracetam

Generic Name
Levetiracetam
Brand Names
Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
Drug Type
Small Molecule
Chemical Formula
C8H14N2O2
CAS Number
102767-28-2
Unique Ingredient Identifier
44YRR34555
Background

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...

Indication

Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...

Associated Conditions
Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
Associated Therapies
-
Clinical Trials
Related News

Levetiracetam to Prevent Post-Traumatic Epilepsy

Phase 2
Completed
Conditions
Epilepsy
Post-traumatic Epilepsy
Interventions
Drug: Levetiracetam
First Posted Date
2011-11-01
Last Posted Date
2016-01-13
Lead Sponsor
Pavel Klein
Target Recruit Count
126
Registration Number
NCT01463033
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

MedStar Research Institute, Washington, District of Columbia, United States

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Phase 2
Completed
Conditions
Epilepsy
Partial Onset Seizures
Interventions
Drug: Levetiracetam
First Posted Date
2011-08-02
Last Posted Date
2013-03-07
Lead Sponsor
UCB Japan Co. Ltd.
Target Recruit Count
16
Registration Number
NCT01407523
Locations
🇯🇵

1, Niigata-city, Niigata, Japan

🇯🇵

2, Shizuoka-city, Shizuoka, Japan

🇯🇵

3, Kodaira-city, Tokyo, Japan

and more 1 locations

An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures

First Posted Date
2011-07-21
Last Posted Date
2017-08-15
Lead Sponsor
UCB Pharma
Target Recruit Count
44
Registration Number
NCT01398956
Locations
🇯🇵

105, Kokubunji, Japan

🇯🇵

162, Himeji, Japan

🇯🇵

110, Hiroshima, Japan

and more 29 locations

Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Levetiracetam
First Posted Date
2011-07-14
Last Posted Date
2011-10-06
Lead Sponsor
UCB Pharma
Target Recruit Count
25
Registration Number
NCT01394224

Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization

Phase 3
Completed
Conditions
Epilepsy
Partial Seizures
Interventions
Drug: Levetiracetam
Drug: Placebo
First Posted Date
2011-07-13
Last Posted Date
2016-10-31
Lead Sponsor
Ache Laboratorios Farmaceuticos S.A.
Target Recruit Count
126
Registration Number
NCT01392768

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

Phase 3
Terminated
Conditions
Epilepsy, Partial
Interventions
Drug: Lacosamide
Drug: Levetiracetam
First Posted Date
2011-06-17
Last Posted Date
2017-08-28
Lead Sponsor
UCB Pharma
Target Recruit Count
11
Registration Number
NCT01375374
Locations
🇩🇪

2, Bielefeld, Germany

🇦🇹

12, Salzburg, Austria

🇪🇸

22, Alcorcon, Spain

and more 4 locations

Add on Lacosamide Versus High Dose Monotherapy

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: lacosamide
Drug: levetiracetam
First Posted Date
2011-04-29
Last Posted Date
2017-05-30
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
56
Registration Number
NCT01345058
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Phase 4
Completed
Conditions
Epilepsy
Interventions
Drug: Levetiracetam
First Posted Date
2011-03-18
Last Posted Date
2018-10-12
Lead Sponsor
Drexel University College of Medicine
Target Recruit Count
24
Registration Number
NCT01318408
Locations
🇺🇸

Drexel University College of Medicine, Dept of Neurology, Philadelphia, Pennsylvania, United States

A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures

First Posted Date
2011-02-10
Last Posted Date
2015-05-15
Lead Sponsor
UCB Japan Co. Ltd.
Target Recruit Count
13
Registration Number
NCT01292837
Locations
🇯🇵

184, Bunkyo, Japan

🇯🇵

303, Hiroshima, Japan

🇯🇵

309, Bunkyo, Japan

and more 23 locations

Pharmacokinetics of Levetiracetam (Keppra) in Neonates

Completed
Conditions
Seizures
Epilepsy
Interventions
Drug: levetiracetam
First Posted Date
2010-12-16
Last Posted Date
2010-12-16
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
18
Registration Number
NCT01261416
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy